Академический Документы
Профессиональный Документы
Культура Документы
Introduction
The diagnosis of diabetes mellitus in an infant aged lifelong medical therapy. TNDM is more frequent than
≤2 years constitutes a diagnostic and therapeutic chal- PNDM (57% versus 43%).3 Multiple genetic abnormali-
lenge to patients, their families, caregivers and profes- ties have been identified as causes of NDM (Figure 1),
sional diabetes health-care teams. Although clinically some of which also affect the function of the exocrine
distinct from diabetes mellitus with an onset during pancreas and other organ systems (Table 2).
childhood, the complexity of this disorder in infancy
has frequently not received adequate emphasis. Infants Transient neonatal diabetes mellitus
aged ≤2 years represent approximately 4–5% of all pedi- TNDM is caused by overexpression of an imprinted gene Division of
atric diabetes patients (Table 1).1,2 Identification of the region in chromosome 6q24 in about 70% of cases.4,5 Endocrinology and
Diabetes, RWTH
underlying defect facilitates adequate medical treat- Activating mutations of one of the two subunits of the Aachen University,
ment and family counseling. In this Review, we will pancreatic β‑cell ATP-sensitive inward rectifier potassium Pauwelsstraße 30,
discuss the clinical management of diabetes mellitus in (KATP) channel, Kir6.2 (encoded by KCNJ11) and sulfonyl- D‑52074 Aachen,
Germany (B. Karges).
infants, including diagnostic and therapeutic approaches, urea receptor 1 (SUR1; encoded by ABCC8),6,7 are found Department of General
ongoing diabetes care and quality control. in approximately 25% of patients, whereas pre-proinsulin Pediatrics and
Neonatology, University
(INS) gene mutations are even rarer.3,8,9 Further causes Children’s Hospital
Forms of diabetes mellitus in infancy of TNDM are mutations in the zinc finger transcription (T. Meissner),
Several specific etiologies of diabetes mellitus have to factor ZFP57, which result in hypomethylation of multiple Department of Public
Health and German
be considered in infants, including monogenic perma- imprinted loci.10 Diabetes Center
nent or transient forms of neonatal diabetes mellitus In addition to diabetes mellitus, individuals with (A. Icks), Heinrich Heine
University of
(NDM), developmental disorders of the pancreas and TNDM can exhibit neurological symptoms and congeni- Düsseldorf,
autoimmune diabetes mellitus, that is, type 1 diabetes tal heart disease (Table 2). TNDM is often accompanied Moorenstraße 5,
D‑40225 Düsseldorf,
mellitus (T1DM). by severe intrauterine growth retardation that requires
Germany. Department
hospitalization, which leads to an early diagnosis of dia- of Pediatrics, University
Neonatal diabetes mellitus betes mellitus. Patients with 6q24 anomalies have lower of Leipzig, Liebigstraße
20a, D‑04103 Leipzig,
Two types of NDM exist, which exhibit a different clini- birth weight and are, therefore, usually diagnosed at an Germany (T. Kapellen).
cal course. Patients with transient NDM (TNDM) show earlier age than individuals with KCNJ11 or ABCC8 muta- Institute of
Epidemiology and
spontaneous remission at least before 18 months of age, tions.7 After clinical remission, diabetes mellitus recurs in Medical Biometry,
whereas those with permanent NDM (PNDM) require adolescence or early adulthood in approximately 50% of University of Ulm,
patients with TNDM.4,9,11 Albert-Einstein-Allee 41,
D‑89081 Ulm, Germany
Competing interests
(R. W. Holl).
T. Kapellen declares an association with the following
Permanent neonatal diabetes mellitus
companies: Medtronic, Roche. See the article online for Correspondence to:
details of the relationships. The other authors declare no PNDM is most often caused by activating mutations of B. Karges
competing interests. KCNJ11 or ABCC8,6,12–15 which lead to channel overactivity bkarges@ukaachen.de
Dysmorphic features can indicate rare types of NDM, are proposed to elucidate the underlying defect (Box 1).
and additional clinical findings can direct the evaluation Careful investigation of associated clinical findings
to specific genetic defects (Table 2). and target-oriented genetic analysis are helpful to clas-
sify diabetes mellitus in many patients (Table 2).12,27
Diagnostic criteria and procedures Genetic screening should be advised in all individuals
Diabetes mellitus comprises a group of metabolic dis with onset of diabetes mellitus within the first 6 months
orders characterized by chronic hyperglycemia,75 pre- of life because of potential consequences for medical
dominantly caused by insulin deficiency in infants. treatment.64,74,76 If TNDM is suspected, analysis of 6q24
Criteria for the diagnosis of diabetes mellitus in child- anomalies is performed. 74 For those with suspected
hood are based on blood glucose measurements, defined PNDM, sequencing of KCNJ11 is recommended, fol-
as random plasma glucose concentrations ≥11.1 mmol/l lowed by analysis of INS and ABCC8.64,76 As a novel tool,
plus symptoms of diabetes mellitus, or fasting plasma whole-exome sequencing might become useful for further
glucose ≥7.0 mmol/l, or 2 h post-load glucose levels molecular diagnosis in NDM cases that are negative for
≥11.1 mmol/l during an oral glucose challenge test.75 known genetic abnormalities.77
Detection of ketones in blood or urine requires urgent
insulin treatment, as ketoacidosis can occur rapidly. Differences between infants and children
An HbA1c level ≥6.5% has been accepted as a diagnos- Infants with diabetes mellitus differ in their clinical
tic criterion for diabetes mellitus.75 However, neonatal features from children aged >2 years at disease onset
blood contains a high proportion of fetal hemoglobin (Table 1). The time from initial presentation of symptoms
(HbF), whereas hemoglobin A (HbA) accounts for only to diagnosis is shorter in infants than in older children.2
10–20%. During the first 6 months of life, HbF is gradu- At time of diagnosis, infants have higher blood glucose
ally replaced by HbA. Therefore, HbA1c is not suitable and lower HbA1c and C‑peptide levels than children
to diagnose diabetes mellitus in infants aged <6 months. aged >2 years, which suggests a faster process of β‑cell
Once the diagnosis of diabetes mellitus has been destruction in younger patients.1,2 Infants with type 1
established in an infant, specific diagnostic procedures diabetes mellitus (T1DM) have increased genetic disease
Nucleus PDX1,
Treatment and management with ER PTF1A,
Citric
Insulin treatment is acutely required in most infants with GLIS3, PAX6,
acid
RFX6,
newly diagnosed diabetes mellitus to treat or prevent NEUROD1, cycle
NEUROG3
ketoacidosis and dehydration and to allow weight gain.
Rarely, spontaneous normalization of blood glucose in ATP/ADP
Insulin
asymptomatic ketone-negative neonates with TNDM can processing Insulin-containing
granula Closure
occur that justifies withholding insulin therapy. In familial K+
Ca2+
PNDM due to activating KATP channel mutations, sulfonyl
KATP
urea therapy has been successfully initiated in an insulin- VDCC channel SUR1
naive neonate.78 The majority of children diagnosed with Kir6.2
diabetes mellitus during infancy will have T1DM, requir- Insulin
secretion Depolarization K+
ing permanent insulin substitution, which presents a par- Ca2+
ticular challenge in these very young children with respect b Glucose
to precise and flexible dosage.
GLUT2
Box 1 | Diagnostic procedures in infants with diabetes at initial diagnosis children with T1DM found no differences in metabolic
■■ Detailed family history including consanguinity, gestational diabetes mellitus control between CSII and MDI.86,90 Infants starting CSII
and early-onset type 2 diabetes mellitus treatment at diabetes onset had better long-term metabolic
■■ Evaluation for associated clinical features including birth weight, dysmorphic control with less frequent hypoglycemic events than those
features, umbilical hernia, macroglossia and skeletal dysplasia on MDI therapy over 5 years.91 Basal insulin substitution
■■ Ultrasonography of abdomen (pancreas agenesis, renal abnormalities) and brain
with CSII depends on age, body weight and duration of
(structural abnormalities) diabetes mellitus in pediatric patients, calculated for chil-
■■ Determination of chymotrypsin-like elastase family member 3B or chymotrypsin
dren aged 0–5 years as 0.25 IU/kg, for 6–12 year-olds as
(to detect exocrine pancreatic insufficiency) 0.33 IU/kg, and for those aged >12–18 years as 0.43 IU/kg
■■ In patients aged ≤6 months: target-oriented molecular analysis starting with
with age-specific circadian variation.81
the most probable entities (for example, 6q24 anomalies, KCNJ11, ABCC8, INS)
and evaluation of first-degree relatives by oral glucose challenge test Sulfonylurea
■■ Analysis of autoantibodies to GAD2, ICA512, islet cells, insulin and ZnT8 Identification of an activating KATP channel mutation in
an infant with diabetes mellitus enables switching from
■■ In antibody-negative infants with disease onset between 6 and 12 months of age
consider analysis of KCNJ11 and ABCC8 because of therapeutic implications insulin injections to oral sulfonylurea treatment in >90%
of affected patients.19,20 Gain-of-function in the pore-
forming Kir6.2 subunits or regulatory SUR1 subunits of
100 – Insulin pump (CSII) the KATP channel induces hyperglycemia due to impaired
90 – 4+ injections insulin secretion (Figures 4a,b). Binding of sulfonylurea
3 injections to SUR1 induces ATP-independent channel closure in
80 – 1–2 injections response to high glucose, resulting in insulin secretion
(Figure 4c). Sulfonylurea compounds also alleviate extra-
70 –
Proportion of patients (%)
treatment according to current guidelines, translating psychological care by mental-health professionals should
this knowledge into everyday self-management behavior be offered to caregivers.
and emotional coping with the chronic disease is part of
educational interventions.112,113 Ongoing diabetes care
Signs of hypoglycemia in infants can be more diffi- Programs and structures
cult to recognize and may be expressed by behavioral To maintain optimal glucose control and quality of care,
changes, including irritability and inconsolable crying.114 ongoing consultations in specialized outpatient clinics
Hypog lycemia is more common in children aged are advised every 3 months. During the visits, insulin
<5 years with diabetes mellitus115,116 and may be more or other medication, blood glucose records, history of
detrimental than in older children. Partial cognitive defi- hypoglycemia or ketoacidosis, nutrition, intercurrent
cits in children with early-onset diabetes mellitus have health problems, developmental milestones and diabetes-
been explained by frequent and early exposure to severe specific knowledge of parents are assessed. 130 Physical
hypoglycemia,115 whereas another study found associ examination includes weight, height, blood pressure
ations between cognitive function and the degree of dia- and inspection of insulin injection and blood glucose
betic ketoacidosis at diagnosis and elevated long-term monitoring sites. Measurement of HbA1c levels is suitable
HbA1c levels but not with hypoglycemia.117 In general, to monitor glycemic control in infants aged >6 months
hyperglycemia and hypoglycemia are linked to adverse but does not necessarily reflect average blood glucose in
neurological outcomes.118,119 infants <6 months. Diabetes-associated diseases includ-
Clinical management during acute infections (sick day ing hypothyroidism and celiac disease131,132 and lipid
management) in infants with diabetes mellitus requires parameters are typically screened. Microvascular and
frequent blood glucose monitoring, regular intake of easily macrovascular diabetes complications are uncommon
digestible food or sugar-containing fluids, and insulin in infants, and general agreement exists that eye or renal
dose adjustments to prevent ketoacidosis, dehydration examinations are not required during the first 5 years
and hyperglycemia or hypoglycemia.120 Determination after diagnosis.
of blood 3‑hydroxybutyrate using test strips might be Continuous up-to-date advice provided by the dia
superior to urine ketone sticks for the detection and treat- betes care team to the family provides a basis for skilled
ment of diabetic ketosis.121 Parents should be trained to self-management. The specialized multidisciplinary
manage sick days and, therefore, clinicians should provide diab etes care team for infants with diabetes mellitus
them with written information, adequate amounts of involves a pediatrician, diabetes nurse or educator, dieti-
glucose and ketone or 3‑hydroxybutyrate test strips, a cian, social worker and/or psychologist in partnership
glucagon kit to treat severe hypoglycemia, and around- with the patient and the family.112,130 Beside ambulatory
the-clock access to the diabetes care team.120 To achieve diab etes care, hospitalization can be necessary in the
social integration of the infant with diabetes mellitus case of metabolic deterioration. Additional tools and
within a nursery, comprehensive information on the resources of diabetes teams include telecommunication
disease should be offered to all care providers. and computer interfacing with blood glucose meters,
CGM sensors and insulin pumps, which enable direct
Psychosocial support interaction between visits.130,133
The diagnosis of diabetes mellitus in an infant is often
associated with massive changes of everyday life for the Quality control
entire family. Parents should be advised to make regular To investigate outcomes of care in infant-onset diabetes
meal plans with carbohydrate counting, glucose read- mellitus, prospective data systems have been established
ings and insulin injections. Instructions are needed for by national networks.134–136 Major differences in metabolic
handling of unforeseen situations, for example, when outcome have been demonstrated between international
infants reject blood glucose measurements and insulin pediatric diabetes centers.137 Including more than 38,000
injections. It may be difficult to distinguish normal children with diabetes aged 0–18 years, the prospective
infant behavior from diabetes-related mood changes.122 diabetes documentation initiative (DPV), which contains
Glucose measurements and insulin injections admini data from Germany and Austria, is one of the largest data
stered by parents and caregivers might be perceived documentation systems for childhood diabetes mellitus
as painful.122,123 Parents often feel increased emotional worldwide.131,132,138 This and other national initiatives have
stress, anxiety and depression.124,125 been used to evaluate indicators of childhood diabetes
High levels of family functioning improve treat- care, including the frequency of out-patient visits, hos-
ment adherence and glycemic control, whereas family pitalization, rates of severe hypoglycemia and diabetic
conflicts, single parenthood, lower income, migration ketoacidosis and other outcomes.134–136 The DPV has
background and psychological maladjustment predict been pivotal to characterize common and rare forms of
poor metabolic control.68,126 The psychosocial resources neonatal diabetes mellitus at the population level.49 The
of the family should be continuously evaluated from design and conductance of research initiatives in pedi
disease onset, to provide sufficient support, especially atric diabetology, focusing on questions specific to infants
for mothers. 127 Given that socioemotional support with diabetes mellitus and taking into account the ethical
and psychological interventions can improve glycemic implications of research in young children, is a highly
control in young children with diabetes mellitus,128,129 relevant challenge for the future.
1. Komulainen, J. et al. Clinical, autoimmune, and potassium-channel subunit Kir6.2 and 27. Russo, L. et al. Permanent diabetes during the
genetic characteristics of very young children permanent neonatal diabetes. N. Engl. J. Med. first year of life: multiple gene screening in 54
with type 1 diabetes. Childhood Diabetes in 350, 1838–1849 (2004). patients. Diabetologia 54, 1693–1701 (2011).
Finland (DiMe) Study Group. Diabetes Care 22, 15. Sagen, J. V. et al. Permanent neonatal diabetes 28. Rubio-Cabezas, O. et al. Wolcott–Rallison
1950–1955 (1999). due to mutations in KCNJ11 encoding Kir6.2: syndrome is the most common genetic cause of
2. Nimri, R., Phillip, M. & Shalitin, S. Children patient characteristics and initial response to permanent neonatal diabetes in
diagnosed with diabetes during infancy have sulfonylurea therapy. Diabetes 53, 2713–2718 consanguineous families. J. Clin. Endocrinol.
unique clinical characteristics. Horm. Res. 67, (2004). Metab. 94, 4162–4170 (2009).
263–267 (2007). 16. de Wet, H. et al. Increased ATPase activity 29. Senée, V. et al. Wolcott-Rallison syndrome:
3. Aguilar-Bryan, L. & Bryan, J. Neonatal diabetes produced by mutations at arginine-1380 in clinical, genetic, and functional study of EIF2AK3
mellitus. Endocr. Rev. 29, 265–291 (2008). nucleotide-binding domain 2 of ABCC8 causes mutations and suggestion of genetic
4. Metz, C. et al. Neonatal diabetes mellitus: neonatal diabetes. Proc. Natl Acad. Sci. USA heterogeneity. Diabetes 53, 1876–1883 (2004).
chromosomal analysis in transient and 104, 18988–18992 (2007). 30. Bennett, C. L. et al. The immune dysregulation,
permanent cases. J. Pediatr. 141, 483–489 17. Proks, P. et al. A heterozygous activating polyendocrinopathy, enteropathy, X-linked
(2002). mutation in the sulphonylurea receptor SUR1 syndrome (IPEX) is caused by mutations of
5. Temple, I. K. et al. Transient neonatal diabetes: (ABCC8) causes neonatal diabetes. Hum. Mol. FOXP3. Nat. Genet. 27, 20–21 (2001).
widening the understanding of the Genet. 15, 1793–1800 (2006). 31. Rubio-Cabezas, O. et al. Clinical heterogeneity in
etiopathogenesis of diabetes. Diabetes 49, 18. Thomas, P. M. et al. Mutations in the patients with FOXP3 mutations presenting with
1359–1366 (2000). sulfonylurea receptor gene in familial persistent permanent neonatal diabetes. Diabetes Care 32,
6. Babenko, A. P. et al. Activating mutations in the hyperinsulinemic hypoglycemia of infancy. 111–116 (2009).
ABCC8 gene in neonatal diabetes mellitus. Science 268, 426–429 (1995). 32. Rubio-Cabezas, O. et al. Permanent neonatal
N. Engl. J. Med. 355, 456–466 (2006). 19. Pearson, E. R. et al. Switching from insulin to diabetes and enteric anendocrinosis associated
7. Flanagan, S. E. et al. Mutations in ATP-sensitive oral sulfonylureas in patients with diabetes due with biallelic mutations in NEUROG3. Diabetes
K+ channel genes cause transient neonatal to Kir6.2 mutations. N. Engl. J. Med. 355, 60, 1349–1353 (2011).
diabetes and permanent diabetes in childhood 467–477 (2006). 33. Rubio-Cabezas, O. et al. Homozygous mutations
or adulthood. Diabetes 56, 1930–1937 (2007). 20. Rafiq, M. et al. Effective treatment with oral in NEUROD1 are responsible for a novel
8. Garin, I. et al. Recessive mutations in the INS sulfonylureas in patients with diabetes due to syndrome of permanent neonatal diabetes and
gene result in neonatal diabetes through sulfonylurea receptor 1 (SUR1) mutations. neurological abnormalities. Diabetes 59,
reduced insulin biosynthesis. Proc. Natl Acad. Diabetes Care 31, 204–209 (2008). 2326–2331 (2011).
Sci. USA 107, 3105–3110 (2010). 21. Zwaveling-Soonawala, N. et al. Successful transfer 34. Wang, J. et al. Mutant neurogenin-3 in congenital
9. Mackay, D. J. & Temple, I. K. Transient neonatal to sulfonylurea therapy in an infant with malabsorptive diarrhea. N. Engl. J. Med. 355,
diabetes mellitus type 1. Am. J. Med. Genet. C developmental delay, epilepsy and neonatal 270–280 (2006).
Semin. Med. Genet. 154C, 335–342 (2010). diabetes (DEND) syndrome and a novel ABCC8 35. Dimitri, P. et al. Novel GLIS3 mutations
10. Mackay, D. J. et al. Hypomethylation of multiple gene mutation. Diabetologia 54, 469–471 (2011). demonstrate an extended multisystem
imprinted loci in individuals with transient 22. Slingerland, A. S. et al. Referral rates for phenotype. Eur. J. Endocrinol. 164, 437–443
neonatal diabetes is associated with mutations diagnostic testing support an incidence of (2011).
in ZFP57. Nat. Genet. 40, 949–951 (2008). permanent neonatal diabetes in three European 36. Senée, V. et al. Mutations in GLIS3 are
11. Søvik, O. et al. Familial occurrence of neonatal countries of at least 1 in 260,000 live births. responsible for a rare syndrome with neonatal
diabetes with duplications in chromosome Diabetologia 52, 1683–1685 (2009). diabetes mellitus and congenital hypothyroidism.
6q24: treatment with sulfonylurea and 40-yr 23. Colombo, C. et al. Seven mutations in the human Nat. Genet. 38, 682–687 (2006).
follow-up. Pediatr. Diabetes http://dx.doi.org/ insulin gene linked to permanent neonatal/ 37. Solomon, B. D. et al. Compound heterozygosity
10.1111/j.1399-5448.2011.00776.x. infancy-onset diabetes mellitus. J. Clin. Invest. for mutations in PAX6 in a patient with complex
12. Edghill, E. L. et al. Insulin mutation screening in 118, 2148–2156 (2008). brain anomaly, neonatal diabetes mellitus, and
1,044 patients with diabetes: mutations in the 24. Polak, M. et al. Heterozygous missense microophthalmia. Am. J. Med. Genet. A 149A,
INS gene are a common cause of neonatal mutations in the insulin gene are linked to 2543–2546 (2009).
diabetes but a rare cause of diabetes diagnosed permanent diabetes appearing in the neonatal 38. Wen, J. H. et al. Paired box 6 (PAX6) regulates
in childhood or adulthood. Diabetes 57, period or in early infancy: a report from the glucose metabolism via proinsulin processing
1034–1042 (2008). French ND (Neonatal Diabetes) Study Group. mediated by prohormone convertase 1/3
13. Ellard, S. et al. Permanent neonatal diabetes Diabetes 57, 1115–1119 (2008). (PC1/3). Diabetologia 52, 504–513 (2009).
caused by dominant, recessive, or compound 25. Støy, J. et al. Insulin gene mutations as a cause 39. Bergmann, A. K. et al. Thiamine-responsive
heterozygous SUR1 mutations with opposite of permanent neonatal diabetes. Proc. Natl megaloblastic anemia: identification of novel
functional effects. Am. J. Hum. Genet. 81, Acad. Sci. USA 104, 15040–15044 (2007). compound heterozygotes and mutation update.
375–382 (2007). 26. Njølstad, P. R. et al. Neonatal diabetes mellitus J. Pediatr. 155, 888–892 e1 (2009).
14. Gloyn, A. L. et al. Activating mutations due to complete glucokinase deficiency. N. Engl. 40. Labay, V. et al. Mutations in SLC19A2 cause
in the gene encoding the ATP-sensitive J. Med. 344, 1588–1592 (2001). thiamine-responsive megaloblastic anaemia
associated with diabetes mellitus and deafness. 59. Zipitis, C. S. & Akobeng, A. K. Vitamin D 77. Bonnefond, A. et al. Molecular diagnosis of
Nat. Genet. 22, 300–304 (1999). supplementation in early childhood and risk neonatal diabetes mellitus using next-generation
41. Kentrup, H., Altmüller, J., Pfäffle, R. & of type 1 diabetes: a systematic review and sequencing of the whole exome. Plos ONE 5,
Heimann, G. Neonatal diabetes mellitus with meta-analysis. Arch. Dis. Child. 93, 512–517 e13630 (2010).
hypergalactosemia. Eur. J. Endocrinol. 141, (2008). 78. Wambach, J. A., Marshall, B. A., Koster, J. C.,
379–381 (1999). 60. Harder, T. et al. Birth weight, early weight gain, White, N. H. & Nichols, C. G. Successful
42. Santer, R. et al. Mutations in GLUT2, the gene for and subsequent risk of type 1 diabetes: sulfonylurea treatment of an insulin-naive
the liver-type glucose transporter, in patients systematic review and meta-analysis. Am. J. neonate with diabetes mellitus due to a KCNJ11
with Fanconi–Bickel syndrome. Nat. Genet. 17, Epidemiol. 169, 1428–1436 (2009). mutation. Pediatr. Diabetes 11, 286–288 (2010).
324–326 (1997). 61. Vaarala, O., Atkinson, M. A. & Neu, J. The 79. Danne, T. et al. A comparison of postprandial and
43. Yoo, H. W., Shin, Y. L., Seo, E. J. & Kim, G. H. “perfect storm” for type 1 diabetes: the complex preprandial administration of insulin aspart in
Identification of a novel mutation in the GLUT2 interplay between intestinal microbiota, gut children and adolescents with type 1 diabetes.
gene in a patient with Fanconi–Bickel syndrome permeability, and mucosal immunity. Diabetes Diabetes Care 26, 2359–2364 (2003).
presenting with neonatal diabetes mellitus and 57, 2555–2562 (2008). 80. Danne, T. et al. Parental preference of prandial
galactosaemia. Eur. J. Pediatr. 161, 351–353 62. Dahlquist, G. G., Nyström, L. & Patterson, C. C. insulin aspart compared with preprandial human
(2002). Incidence of type 1 diabetes in Sweden among insulin in a basal-bolus scheme with NPH insulin
44. Nicolino, M. et al. A novel hypomorphic PDX1 individuals aged 0–34 years, 1983–2007: in a 12-wk crossover study of preschool children
mutation responsible for permanent neonatal an analysis of time trends. Diabetes Care 34, with type 1 diabetes. Pediatr. Diabetes 8,
diabetes with subclinical exocrine deficiency. 1754–1759 (2011). 278–285 (2007).
Diabetes 59, 733–740 (2010). 63. Patterson, C. C., Dahlquist, G. G., Gyürüs, E., 81. Bachran, R. et al. Basal rates and circadian
45. Stoffers, D. A., Zinkin, N. T., Stanojevic, V., Green, A. & Soltész, G. Incidence trends for profiles in continuous subcutaneous insulin
Clarke, W. L. & Habener, J. F. Pancreatic childhood type 1 diabetes in Europe during infusion (CSII) differ for preschool children,
agenesis attributable to a single nucleotide 1989–2003 and predicted new cases 2005–20: prepubertal children, adolescents and young
deletion in the human IPF1 gene coding a multicentre prospective registration study. adults. Pediatr. Diabetes http://dx.doi.org/
sequence. Nat. Genet. 15, 106–110 (1997). Lancet 373, 2027–2033 (2009). 10.1111/j.1399-5448.2011.00777.x.
46. Sellick, G. S. et al. Mutations in PTF1A cause 64. Rubio-Cabezas, O., Klupa, T. & Malecki, M. T. 82. Szypowska, A., Lipka, M., Błazik, M., Groele, L.
pancreatic and cerebellar agenesis. Nat. Genet. Permanent neonatal diabetes mellitus--the & Pańkowska, E. Insulin requirement in
36, 1301–1305 (2004). importance of diabetes differential diagnosis in preschoolers treated with insulin pumps at the
47. Smith, S. B. et al. Rfx6 directs islet formation neonates and infants. Eur. J. Clin. Invest. 41, onset of type 1 diabetes mellitus. Acta Paediatr.
and insulin production in mice and humans. 323–333 (2011). 98, 527–530 (2009).
Nature 463, 775–780 (2010). 65. Berhan, Y., Waernbaum, I., Lind, T., Möllsten, A. 83. Alemzadeh, R., Berhe, T. & Wyatt, D. T. Flexible
48. Beardsall, K., Pesterfield, C. L. & Acerini, C. L. & Dahlquist, G. Thirty years of prospective insulin therapy with glargine insulin improved
Neonatal diabetes and insulin pump therapy. nationwide incidence of childhood type 1 glycemic control and reduced severe
Arch. Dis. Child. Fetal Neonatal Ed. 96, diabetes: the accelerating increase by time hypoglycemia among preschool-aged children
F223–F224 (2011). tends to level off in Sweden. Diabetes 60, with type 1 diabetes mellitus. Pediatrics 115,
49. Grulich-Henn, J. et al. Entities and frequency of 577–581 (2011). 1320–1324 (2005).
neonatal diabetes: data from the diabetes 66. Altamirano-Bustamante, N. et al. Economic 84. Tubiana-Rufi, N. Insulin pump therapy in neonatal
documentation and quality management system family burden of metabolic control in children diabetes. Endocr. Dev. 12, 67–74 (2007).
(DPV). Diabet. Med. 27, 709–712 (2010). and adolescents with type 1 diabetes mellitus. 85. Kapellen, T. M. et al. Changes in the use of
50. Vaziri-Sani, F. et al. ZnT8 autoantibody titers in J. Pediatr. Endocrinol. Metab. 21, 1163–1168 analogue insulins in 37,206 children and
type 1 diabetes patients decline rapidly after (2008). adolescents with type 1 diabetes in 275 German
clinical onset. Autoimmunity 43, 598–606 67. Ying, A. K. et al. Predictors of direct costs of and Austrian centers during the last twelve
(2010). diabetes care in pediatric patients with type 1 years. Exp. Clin. Endocrinol. Diabetes 117,
51. Erlich, H. et al. HLA DR-DQ haplotypes and diabetes. Pediatr. Diabetes 12, 177–182 (2011). 329–335 (2009).
genotypes and type 1 diabetes risk: analysis of 68. Icks, A. et al. Direct costs of pediatric diabetes 86. Fox, L. A., Buckloh, L. M., Smith, S. D.,
the type 1 diabetes genetics consortium care in Germany and their predictors. Exp. Clin. Wysocki, T. & Mauras, N. A randomized
families. Diabetes 57, 1084–1092 (2008). Endocrinol. Diabetes 112, 302–309 (2004). controlled trial of insulin pump therapy in young
52. Barrett, J. C. et al. Genome-wide association 69. Wiréhn, A. B., Andersson, A., Ostgren, C. J. & children with type 1 diabetes. Diabetes Care 28,
study and meta-analysis find that over 40 loci Carstensen, J. Age-specific direct healthcare 1277–1281 (2005).
affect risk of type 1 diabetes. Nat. Genet. 41, costs attributable to diabetes in a Swedish 87. Mack-Fogg, J. E., Orlowski, C. C. & Jospe, N.
703–707 (2009). population: a register-based analysis. Diabet. Continuous subcutaneous insulin infusion in
53. Concannon, P. et al. Genome-wide scan for Med. 25, 732–737 (2008). toddlers and children with type 1 diabetes
linkage to type 1 diabetes in 2,496 multiplex 70. Bächle, C. et al. Direct diabetes-related costs in mellitus is safe and effective. Pediatr. Diabetes
families from the Type 1 Diabetes Genetics young patients with early onset and long-lasting 6, 17–21 (2005).
Consortium. Diabetes 58, 1018–1022 (2009). type 1 diabetes [a864]. Diabetologia 54 88. Pańkowska, E., Błazik, M., Dziechciarz, P.,
54. Holmberg, H., Wahlberg, J., Vaarala, O. & (Suppl. 1), S353 (2011). Szypowska, A. & Szajewska, H. Continuous
Ludvigsson, J. Short duration of breast-feeding 71. Greeley, S. A. et al. The cost-effectiveness of subcutaneous insulin infusion vs. multiple daily
as a risk-factor for beta-cell autoantibodies in personalized genetic medicine: the case of injections in children with type 1 diabetes:
5‑year‑old children from the general population. genetic testing in neonatal diabetes. Diabetes a systematic review and meta-analysis of
Br. J. Nutr. 97, 111–116 (2007). Care 34, 622–627 (2011). randomized control trials. Pediatr. Diabetes 10,
55. Norris, J. M. et al. Timing of initial cereal 72. Hekkala, A., Reunanen, A., Koski, M., Knip, M. & 52–58 (2009).
exposure in infancy and risk of islet Veijola, R. Age-related differences in the 89. Berghaeuser, M. A. et al. Continuous
autoimmunity. JAMA 290, 1713–1720 (2003). frequency of ketoacidosis at diagnosis of type 1 subcutaneous insulin infusion in toddlers
56. Virtanen, S. M. et al. Early introduction of root diabetes in children and adolescents. Diabetes starting at diagnosis of type 1 diabetes mellitus.
vegetables in infancy associated with advanced Care 33, 1500–1502 (2010). A multicenter analysis of 104 patients from 63
ss-cell autoimmunity in young children with 73. Dahlquist, G. & Källén, B. Mortality in childhood- centres in Germany and Austria. Pediatr.
human leukocyte antigen-conferred susceptibility onset type 1 diabetes: a population-based study. Diabetes 9, 590–595 (2008).
to type 1 diabetes. Diabet. Med. 28, 965–971 Diabetes Care 28, 2384–2387 (2005). 90. Wilson, D. M. et al. A two-center randomized
(2011). 74. Temple, I. K. & Shield, J. P. 6q24 transient controlled feasibility trial of insulin pump therapy
57. Ziegler, A. G., Schmid, S., Huber, D., Hummel, M. neonatal diabetes. Rev. Endocr. Metab. Disord. in young children with diabetes. Diabetes Care
& Bonifacio, E. Early infant feeding and risk of 11, 199–204 (2010). 28, 15–19 (2005).
developing type 1 diabetes-associated 75. American Diabetes Association. Diagnosis and 91. Sulmont, V. et al. Metabolic control in children
autoantibodies. JAMA 290, 1721–1728 (2003). classification of diabetes mellitus. Diabetes Care with diabetes mellitus who are younger than
58. Yeung, W. C., Rawlinson, W. D. & Craig, M. E. 33 (Suppl. 1), S62–S69 (2010). 6 years at diagnosis: continuous subcutaneous
Enterovirus infection and type 1 diabetes 76. Edghill, E. L., Flanagan, S. E. & Ellard, S. insulin infusion as a first line treatment?
mellitus: systematic review and meta-analysis of Permanent neonatal diabetes due to activating J. Pediatr. 157, 103–107 (2010).
observational molecular studies. BMJ 342, d35 mutations in ABCC8 and KCNJ11. Rev. Endocr. 92. Müller, G. The molecular mechanism of
(2011). Metab. Disord. 11, 193–198 (2010). the insulin-mimetic/sensitizing activity of the
antidiabetic sulfonylurea drug Amaryl. Mol. Med. adolescents with diabetes. Pediatr. Diabetes 10 and family social situation on glycemic control
6, 907–933 (2000). (Suppl. 12), 100–117 (2009). and medical care in children with type I diabetes
93. Hattersley, A. & Pearson, E. Transferring patients 110. Sauer, C. W. & Kim, J. H. Human milk mellitus. Acta Paediatr. 89, 1462–1468 (2000).
with diabetes due to Kir6.2 mutation from macronutrient analysis using point‑of‑care near- 127. Sullivan-Bolyai, S. et al. Helping other mothers
insulin to suphonylureas. Diabetes Genes infrared spectrophotometry. J. Perinatol. 31, effectively work at raising young children with
[online], http://www.diabetesgenes.org/ 339–343 (2011). type 1 diabetes. Diabetes Educ. 30, 476–484
content/transferring-patients-diabetes-due- 111. Detlofson, I., Kroon, M. & Aman, J. Oral bedtime (2004).
kir62-mutation-insulin-sulphonylureas (2011). cornstarch supplementation reduces the risk for 128. Chisholm, V. et al. Predictors of treatment
94. Klupa, T. et al. Efficacy and safety of sulfonylurea nocturnal hypoglycaemia in young children with adherence in young children with type 1
use in permanent neonatal diabetes due to type 1 diabetes. Acta Paediatr. 88, 595–597 diabetes. J. Adv. Nurs. 57, 482–493 (2007).
KCNJ11 gene mutations: 34-month median (1999). 129. Winkley, K., Ismail, K., Landau, S. & Eisler, I.
follow-up. Diabetes Technol. Ther. 12, 387–391 112. Lange, K., Sassmann, H., von Schütz, W., Psychological interventions to improve glycaemic
(2010). Kordonouri, O. & Danne, T. Prerequisites for age- control in patients with type 1 diabetes:
95. Ziegler, R. et al. Frequency of SMBG correlates appropriate education in type 1 diabetes: systematic review and meta-analysis of
with HbA1c and acute complications in children a model programme for paediatric diabetes randomised controlled trials. BMJ 333, 65
and adolescents with type 1 diabetes. Pediatr. education in Germany. Pediatr. Diabetes (2006).
Diabetes 12, 11–17 (2011). 8 (Suppl. 6), 63–71 (2007). 130. Pihoker, C., Forsander, G., Wolfsdorf, J. &
96. Kordonouri, O. et al. Sensor-augmented pump 113. Swift, P. G. Diabetes education in children and Klingensmith, G. J. The delivery of ambulatory
therapy from the diagnosis of childhood type 1 adolescents. Pediatr. Diabetes 10 (Suppl. 12), diabetes care to children and adolescents with
diabetes: results of the Paediatric Onset Study 51–57 (2009). diabetes. Pediatr. Diabetes 10 (Suppl. 12),
(ONSET) after 12 months of treatment. 114. McCrimmon, R. J., Gold, A. E., Deary, I. J., 58–70 (2009).
Diabetologia 53, 2487–2495 (2010). Kelnar, C. J. & Frier, B. M. Symptoms of 131. Fröhlich-Reiterer, E. E. et al. Anthropometry,
97. Deiss, D., Kordonouri, O., Meyer, K. & Danne, T. hypoglycemia in children with IDDM. Diabetes metabolic control, and follow-up in children
Long hypoglycaemic periods detected by Care 18, 858–861 (1995). and adolescents with type 1 diabetes mellitus
subcutaneous continuous glucose monitoring in 115. Hershey, T. et al. Frequency and timing of severe and biopsy-proven celiac disease. J. Pediatr.
toddlers and pre-school children with diabetes hypoglycemia affects spatial memory in children 158, 589–593 e2 (2011).
mellitus. Diabet. Med. 18, 337–338 (2001). with type 1 diabetes. Diabetes Care 28, 132. Warncke, K. et al. Polyendocrinopathy in children,
98. Slover, R. H. et al. Effectiveness of sensor- 2372–2377 (2005). adolescents, and young adults with type 1
augmented pump therapy in children and 116. Wagner, V. M., Grabert, M. & Holl, R. W. Severe diabetes: a multicenter analysis of 28,671
adolescents with type 1 diabetes in the STAR 3 hypoglycaemia, metabolic control and diabetes patients from the German/Austrian DPV-Wiss
study. Pediatr. Diabetes http://dx.doi.org/ management in children with type 1 diabetes in database. Diabetes Care 33, 2010–2012
10.1111/j.1399-5448.2011.00793.x. the decade after the Diabetes Control and (2010).
99. Tamborlane, W. V. et al. Continuous glucose Complications Trial—a large-scale multicentre 133. Jansà, M. et al. Telecare in a structured
monitoring and intensive treatment of type 1 study. Eur. J. Pediatr. 164, 73–79 (2005). therapeutic education programme addressed
diabetes. N. Engl. J. Med. 359, 1464–1476 117. Schoenle, E. J., Schoenle, D., Molinari, L. & to patients with type 1 diabetes and poor
(2008). Largo, R. H. Impaired intellectual development in metabolic control. Diabetes Res. Clin. Pract. 74,
100. Hovorka, R. et al. Overnight closed loop insulin children with Type I diabetes: association with 26–32 (2006).
delivery (artificial pancreas) in adults with type 1 HbA(1c), age at diagnosis and sex. Diabetologia 134. Gerstl, E. M. et al. Metabolic control as reflected
diabetes: crossover randomised controlled 45, 108–114 (2002). by HbA1c in children, adolescents and young
studies. BMJ 342, d1855 (2011). 118. Ferguson, S. C. et al. Influence of an early-onset adults with type-1 diabetes mellitus: combined
101. Elleri, D. et al. Automated overnight closed-loop age of type 1 diabetes on cerebral structure and longitudinal analysis including 27,035 patients
glucose control in young children with type 1 cognitive function. Diabetes Care 28, from 207 centers in Germany and Austria during
diabetes. Diabetes Technol. Ther. 13, 419–424 1431–1437 (2005). the last decade. Eur. J. Pediatr. 167, 447–453
(2011). 119. Northam, E. A. et al. Neuropsychological profiles (2008).
102. Keymeulen, B. et al. Four-year metabolic of children with type 1 diabetes 6 years after 135. Margeirsdottir, H. D., Larsen, J. R.,
outcome of a randomised controlled CD3- disease onset. Diabetes Care 24, 1541–1546 Kummernes, S. J., Brunborg, C. & Dahl-
antibody trial in recent-onset type 1 diabetic (2001). Jorgensen, K. The establishment of a new
patients depends on their age and baseline 120. Brink, S. et al. Sick day management in children national network leads to quality improvement in
residual beta cell mass. Diabetologia 53, 614– and adolescents with diabetes. Pediatr. Diabetes childhood diabetes: implementation of the ISPAD
623 (2010). 10 (Suppl. 12), 146–153 (2009). Guidelines. Pediatr. Diabetes 11, 88–95 (2010).
103. Ludvigsson, J. et al. GAD treatment and insulin 121. Laffel, L. M. et al. Sick day management using 136. Svensson, J., Johannesen, J., Mortensen, H. B. &
secretion in recent-onset type 1 diabetes. blood 3-hydroxybutyrate (3-OHB) compared with Nordly, S. Improved metabolic outcome in a
N. Engl. J. Med. 359, 1909–1920 (2008). urine ketone monitoring reduces hospital visits Danish diabetic paediatric population aged
104. Mastrandrea, L. et al. Etanercept treatment in in young people with T1DM: a randomized 0–18 yr: results from a nationwide continuous
children with new-onset type 1 diabetes: pilot clinical trial. Diabet. Med. 23, 278–284 (2006). Registration. Pediatr. Diabetes 10, 461–467
randomized, placebo-controlled, double-blind 122. Hatton, D. L., Canam, C., Thorne, S. & (2009).
study. Diabetes Care 32, 1244–1249 (2009). Hughes, A. M. Parents’ perceptions of caring for 137. de Beaufort, C. E. et al. Continuing stability of
105. Wherrett, D. K. et al. Antigen-based therapy with an infant or toddler with diabetes. J. Adv. Nurs. center differences in pediatric diabetes care:
glutamic acid decarboxylase (GAD) vaccine in 22, 569–577 (1995). do advances in diabetes treatment improve
patients with recent-onset type 1 diabetes: 123. Karges, B. et al. Low discomfort and pain outcome? The Hvidoere Study Group on
a randomised double-blind trial. Lancet 378, associated with intensified insulin therapy in Childhood Diabetes. Diabetes Care 30,
319–327 (2011). children and adolescents. Diabetes Res. Clin. 2245–2250 (2007).
106. Näntö-Salonen, K. et al. Nasal insulin to Pract. 80, 96–101 (2008). 138. Karges, B. et al. Long-acting insulin analogs and
prevent type 1 diabetes in children with HLA 124. Haugstvedt, A., Wentzel-Larsen, T., Rokne, B. & the risk of diabetic ketoacidosis in children and
genotypes and autoantibodies conferring Graue, M. Perceived family burden and adolescents with type 1 diabetes: a prospective
increased risk of disease: a double-blind, emotional distress: similarities and differences study of 10,682 patients from 271 institutions.
randomised controlled trial. Lancet 372, between mothers and fathers of children with Diabetes Care 33, 1031–1033 (2010).
1746–1755 (2008). type 1 diabetes in a population-based study.
107. Knip, M. et al. Dietary intervention in infancy and Pediatr. Diabetes 12, 107–114 (2011). Acknowledgments
later signs of beta-cell autoimmunity. N. Engl. J. 125. Patton, S. R., Dolan, L. M., Smith, L. B., The authors’ work was supported by the BMBF
Med. 363, 1900–1908 (2010). Thomas, I. H. & Powers, S. W. Pediatric Kompetenznetz Diabetes Mellitus (Competence
108. Couri, C. E. et al. C-peptide levels and insulin parenting stress and its relation to depressive Network for Diabetes Mellitus) funded by the Federal
independence following autologous symptoms and fear of hypoglycemia in parents Ministry of Education and Research (FKZ 01GI0859).
nonmyeloablative hematopoietic stem cell of young children with type 1 diabetes mellitus.
transplantation in newly diagnosed type 1 J. Clin. Psychol. Med. Settings http://dx.doi.org/ Author contributions
diabetes mellitus. JAMA 301, 1573–1579 (2009). 10.1007/s10880-011-9256-1. B. Karges, A. Icks, T. Kapellen and R. W. Holl
109. Smart, C., Aslander-van Vliet, E. & Waldron, S. 126. Forsander, G. A., Sundelin, J. & Persson, B. researched the data for the article. All authors
Nutritional management in children and Influence of the initial management regimen contributed equally to all other aspects of the article.